ESR1 and breast carcinoma: However; definite cut-off values for Ki67 have not yet been decided, and evidence to indicate that patients with low Ki67 LI among those with ER-positive/HER2-negative breast cancer are at a lower risk of breast cancer relapse is limited [10, 11].